12:00 AM
Sep 22, 2008
 |  BC Week In Review  |  Company News  |  Deals

Durect, EpiCept deal

Durect paid $2.3 million to expand its rights and remove future milestone and royalty obligations under its 2006 license to EpiCept's IP covering Eladur bupivacaine...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >